Aerie Pharmaceuticals Announces Public Offering of Common Stock
16 September 2016 - 6:05AM
Business Wire
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class therapies for the treatment of
glaucoma and other diseases of the eye, today announced that it has
commenced a registered underwritten public offering of $50 million
of shares of its common stock.
Cantor Fitzgerald & Co. is acting as the sole underwriter
for the offering.
Aerie intends to use the net proceeds of the offering for
general corporate purposes, including the complete funding of
RhopressaTM commercialization costs, execution of clinical trials
in Japan, commencement of construction of a manufacturing plant in
Ireland and continuation of preclinical activity in support of its
product pipeline, along with ongoing working capital
requirements.
A shelf registration statement relating to the shares is
effective with the Securities and Exchange Commission. The shares
may be offered only by means of a prospectus, including a
prospectus supplement, forming a part of the effective registration
statement. A preliminary prospectus supplement related to the
offering will be filed with the Securities and Exchange Commission
today. An electronic copy of the preliminary prospectus supplement
and the accompanying prospectus relating to the offering will be
available on the website of the Securities and Exchange Commission
at www.sec.gov. Copies of the preliminary prospectus supplement and
the final prospectus supplement, when available, and the
accompanying prospectus relating to the offering may be obtained by
contacting Cantor Fitzgerald & Co., Attn: Capital Markets, 499
Park Ave., 5th Floor, New York, New York 10022, or by telephone at
212-829-7122, or by e-mail at prospectus@cantor.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any securities of Aerie, and shall
not constitute an offer, solicitation or sale of any security in
any state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Aerie Pharmaceuticals, Inc.
Aerie is a clinical-stage pharmaceutical company focused on the
discovery, development and commercialization of first-in-class
therapies for the treatment of patients with glaucoma and other
diseases of the eye. Aerie's two lead product candidates are
once-daiIy IOP-lowering therapies with novel mechanisms of action
to treat patients with glaucoma or ocular hypertension. The NDA
filing for RhopressaTM (netarsudil ophthalmic solution) 0.02% was
submitted in the third quarter of 2016. The second product
candidate, RoclatanTM (netarsudil/latanoprost ophthalmic solution)
0.02%/0.005%, which is a fixed dose combination of RhopressaTM and
widely prescribed PGA latanoprost, currently has two Phase 3
registration trials underway, named Mercury 1 and Mercury 2. If
these trials are successful, a RoclatanTM NDA filing is expected to
take place near year-end 2017. Aerie is also focused on the
development of additional product candidates and technologies in
ophthalmology.
Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. We may, in some cases, use terms
such as “predicts,” “believes,” “potential,” “proposed,”
“continue,” “estimates,” “anticipates,” “expects,” “plans,”
“intends,” “may,” “could,” “might,” “will,” “should,” “exploring,”
“pursuing” or other words that convey uncertainty of future events
or outcomes to identify these forward-looking statements.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things: the success, timing
and cost of our ongoing and anticipated preclinical studies and
clinical trials for our current product candidates, including
statements regarding the timing of initiation and completion of the
studies and trials; our expectations regarding the clinical
effectiveness of our product candidates and results of our clinical
trials; the timing of and our ability to request, obtain and
maintain U.S. Food and Drug Administration or other regulatory
authority approval of, or other action with respect to, our product
candidates; our expectations regarding the commercialization of our
product candidates; our expectations related to the offering
discussed in this press release, including the use of proceeds from
the offering; the potential advantages of our product candidates;
and our plans to pursue development of our product candidates for
additional indications and other therapeutic opportunities. By
their nature, forward-looking statements involve risks and
uncertainties because they relate to events, competitive dynamics
and industry change, and depend on regulatory approvals and
economic circumstances that may or may not occur in the future or
may occur on longer or shorter timelines than anticipated. We
discuss many of these risks in greater detail under the heading
“Risk Factors” in the quarterly and annual reports that we file
with the Securities and Exchange Commission (SEC). Forward-looking
statements are not guarantees of future performance and our actual
results of operations, financial condition and liquidity, and the
development of the industry in which we operate may differ
materially from the forward-looking statements contained in this
press release. Any forward-looking statements that we make in this
press release speak only as of the date of this press release. We
assume no obligation to update our forward-looking statements
whether as a result of new information, future events or otherwise,
after the date of this press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160915006512/en/
Aerie PharmaceuticalsRichard Rubino,
908-947-3540rrubino@aeriepharma.comorBurns McClellan, Inc., on
behalf of Aerie PharmaceuticalsInvestorsAmi Bavishi,
212-213-0006abavishi@burnsmc.comorMediaJustin Jackson,
212-213-0006jjackson@burnsmc.com
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Sep 2023 to Sep 2024